$ZURA News

This biotech stock is a top pick at Guggenheim

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply

Zura Bio to Participate in the Cantor Global Healthcare Conference

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22

Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate

William Blair Starts Zura Bio (ZURA) at Outperform

William Blair Initiates Coverage On Zura Bio with Outperform Rating

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy

Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance

Zura Bio Q1 EPS $(0.22) Misses $(0.18) Estimate

Zura Bio Announces Separation From CFO Eric Hyllengren; Marlyn Mathew Named Principal Accounting And Principal Financial Officer

One Zura Bio Insider Raised Their Stake In The Previous Year

Zura Bio: Momentum Is Real, But TibuSHIELD Needs To Deliver